上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
21期
61-65,77
,共6页
兰标%郭晔堃%钟静芬%时惠麟
蘭標%郭曄堃%鐘靜芬%時惠麟
란표%곽엽곤%종정분%시혜린
新型口服抗凝药%血栓疾病%临床研究
新型口服抗凝藥%血栓疾病%臨床研究
신형구복항응약%혈전질병%림상연구
novel oral anticoagulants%thromboembolic disease%clinical studies
随着新型口服抗凝药物相继批准上市，血栓疾病的治疗又有了新的有效途径。已经通过美国FDA批准的口服抗凝药有达比加群酯、利伐沙班、阿哌沙班。本文综述了以上3个药物的主要临床研究，间接对比了其有效性和安全性。
隨著新型口服抗凝藥物相繼批準上市，血栓疾病的治療又有瞭新的有效途徑。已經通過美國FDA批準的口服抗凝藥有達比加群酯、利伐沙班、阿哌沙班。本文綜述瞭以上3箇藥物的主要臨床研究，間接對比瞭其有效性和安全性。
수착신형구복항응약물상계비준상시，혈전질병적치료우유료신적유효도경。이경통과미국FDA비준적구복항응약유체비가군지、리벌사반、아고사반。본문종술료이상3개약물적주요림상연구，간접대비료기유효성화안전성。
There are some new effective ways in the treatment of thrombotic diseases with novel oral anticoagulants to be approved. So far, there are dabigatran etexilate, rivaroxaban and apixaban on the market after approved by the U.S. FDA. The major clinical studies on these three drugs are reviewed in this article and their effectiveness and safety are indirectly compared.
